Board of Directors
Augustine Lawlor, Chairman of the Board
Managing Director, HealthCare Ventures LLC
Augustine Lawlor has served as a member of the board of directors of Catalyst since 2006. Mr. Lawlor currently serves as Chief Operating Officer of Leap Therapeutics (LPTX). He has been a Managing Director of HealthCare Ventures since 2000. From 1997 to 2000, he served as Chief Operating Officer of LeukoSite, a HealthCare Ventures III, IV and V company. Prior to joining LeukoSite, Mr. Lawlor was Chief Financial Officer and Vice President of Corporate Development for Alpha-Beta Technology. He has held similar positions at both BioSurface Technology and Armstrong Pharmaceuticals. Mr. Lawlor was previously a management consultant with KPMG.
Mr. Lawlor is currently a director of Cardiovascular Systems (CSII), GlobeImmune (GBIM), Promedior, Tensha Therapeutics, HealthCare Pharmaceuticals, Cleveland HeartLab, LLC, GITR, Anexon, and the Slater Center for Biomedical Technology. He served on the Board of Directors of Human Genome Sciences (HGSI) from March 2004 to August 2012 and the board of directors of Replidyne from March 2002 to March 2009.
Mr. Lawlor received a B.A. from the University of New Hampshire and a Master’s degree in Public and Private Management from Yale University.
Errol B. De Souza, Ph.D.
Executive Chairman, Bionomics Ltd.
Errol B. De Souza, Ph.D. served as a member of the board of directors of Targacept (TRGT) from 2004 until the completion of the merger in 2015, and since the merger he has served on the Catalyst Board. Dr. De Souza is currently the Executive Chairman of Bionomics Ltd. He has substantial experience as an executive in the biopharmaceutical industry, having founded companies (Neurocrine Biosciences) and served as President and CEO of several public (Biodel; Synaptic Pharmaceutical Corp.) and private (Archemix and Neuropore) biotech companies. Dr. De Souza has raised several hundred million dollars in capital in private and public sectors and has taken companies public (Neurocrine Biosciences IPO) and sold companies (Synaptic sale to Lundbeck) to provide liquidity and build shareholder value. Over Dr. De Souza’s career, he has served in a number of high-ranking R&D roles, including SVP and U.S. head of R&D for Aventis (1998-2002), co-founder and EVP of R&D at Neurocrine (1992-1998) and Head of CNS at DuPont Merck (1990–1992).
Dr. De Souza serves on the Board of Directors of several public and private companies. He currently serves as a member of the board of directors of Bionomics (BNO.AX). He has served on the board of directors of several public companies including IDEXX Laboratories (IDXX), Neurocrine Biosciences (NBIX), Palatin Technologies (PTN) and Synaptic Pharmaceuticals (SNAP).
Dr. De Souza received his B.A. (Honors) in physiology and his Ph.D. in neuroendocrinology from the University of Toronto and was postdoctoral fellow in neuroscience at The Johns Hopkins University School of Medicine.
Andrea Hunt has served as a member of the board of directors of Catalyst since October 2017. Ms. Hunt served as the Vice President of New Product Gene Therapy, Neuroscience, Oncology and Ophthalmology with Shire from June 2016 until June 2017, where she developed and integrated disease area strategies for Shire’s gene therapy platform, Neuroscience, Oncology and Ophthalmology franchises. She previously served as the Vice President – Global Franchise Head for Blood Disorders with Baxalta from June 2015 to June 2016 before it was acquired by Shire. From 1988 to 2015, Ms. Hunt served in various roles with Baxter Healthcare, most recently as Vice President – Lead BAX855 and Gene Therapy in the Biosciences division from 2014 to June 2015.
Ms. Hunt served as a board member of the Alliance for Regenerative Medicine and is an advisor to the Angiogenesis Foundation.
Ms. Hunt received an M.B.A. from the University of Michigan at Ann Arbor and a B.S. in Hospital Dietetics and B.A. in Foods & Nutrition from the University of Illinois at Urbana-Champaign.
Geoffrey Ling, Ph.D.
Professor of Neurology and Attending Physician, Neuro Critical Care, Johns Hopkins Hospital
Dr. Geoffrey Ling has been Professor of Neurology and Attending Neuro Critical Care Physician at Johns Hopkins Medical Institutions since 2000 and the Emeritus Professor of Neurology, Uniformed Services University of the Health Science since 2017. He has also been Vice-Chair of Research in the Department of Clinical Neurosciences at Inova Fairfax Medical Center, Fairfax, Virginia since 2017. He is the co-founder of Predigen, Inc., a privately held company and the chief executive officer and founder of On Demand Pharmaceuticals, Inc., a privately held company. Dr. Ling is on the boards of several privately held companies which include Wheel Bio, MindX Corp. and NED Biosystems Inc. Dr. Ling served as the director of the Defense Advanced Research Projects Agency (DARPA) Biological Technologies Office from 2004 to 2015. Dr. Ling holds a B.S. in Biology and History from Washington University, a Ph.D. in Pharmacology from Cornell University – Graduate School of Medical Sciences and an M.D. from Georgetown University School of Medicine.
Managing Partner, Portrero Hill Advisors
Ms. Sharon Tetlow has served as Managing Partner of Potrero Hill Advisors since January 2016. Potrero Hill Advisors provides strategic and operational financial support to life science companies through its team of chief financial officers and controllers. Ms. Tetlow was previously the Managing Director of Danforth Advisors from April 2013 to January 2016. She served as Chief Financial Officer of Pathwork Diagnostics, Inc., a privately held biotechnology company, from 2011 to 2013. From 2005 to 2009, she served as Chief Financial Officer of Cell Genesys, Inc., (CEGE) a publicly traded biotechnology company. In connection with her role as managing partner of Potreto Hill Advisors, Ms. Tetlow has led the finance function at several biotechnology and pharmaceutical companies, including 4D Molecular Therapeutics Inc., and Ocera Therapeutics Inc., two privately held companies and Allakos Inc. and CytomX Inc., two publicly traded companies. Ms. Tetlow was previously on the board of directors of Armetheon, Inc., a privately held company. Ms. Tetlow holds a B.A. in Psychology from University of Delaware and an M.B.A. from Stanford University.
Nassim Usman, Ph.D.
President and Chief Executive Officer, Catalyst Biosciences, Inc.
Nassim Usman, Ph.D., served as Chief Executive Officer and a member of the board of directors of Catalyst since 2006. Dr. Usman joined Catalyst from Morgenthaler Ventures, where he is currently a Venture Partner. Prior to joining Morgenthaler in 2005, he was Senior Vice President and Chief Operating Officer at Sirna Therapeutics, which was subsequently acquired by Merck (MRK), from 2004 to 2005, and held various R&D positions at both Sirna and Ribozyme Pharmaceuticals, including Vice President of R&D and Chief Science Officer, from 1992 to 2004. Dr. Usman was an NIH Fogarty and NSERC Postdoctoral Fellow and Scientist in the Departments of Biology and Chemistry at the Massachusetts Institute of Technology from 1987 to 1992. He has authored more than 70 scientific articles and is the named inventor in 130 issued patents and patent applications.
Dr. Usman has served on the boards of Principia Biopharma (NASDAQ:PRNB), Osprey Pharmaceuticals, Archemix Corporation and atugen AG, (Silence therapeutics LSE/AIM: SLN) and the scientific advisory boards of RXi Pharmaceuticals and Noxxon Pharma AG.
Dr. Usman received his B.Sc. (Honours) and Ph.D. in Organic Chemistry from McGill University. In his doctoral dissertation, he developed a method for the solid- phase synthesis of RNA that is widely used in science and in a marketed RNA product (Macugen™).
Mr. Williams was most recently senior vice president of biopharmaceuticals at Novo Nordisk Inc., where he was responsible for the general management of all aspects of the biotechnology business for the U.S. in three therapeutic areas, including hemophilia. Prior to Novo Nordisk, Mr. Williams was vice president of sales in the Respiratory and Dermatology Business Unit at Novartis Pharmaceuticals Corp., where he ran all sales aspects of the respiratory and dermatology businesses. Before joining Novartis, Mr. Williams held numerous sales and marketing positions of increasing responsibility for more than 20 years at Pharmacia & Upjohn Company (acquired by Pfizer in 2002). Mr. Williams served on the board of Biotechnology Innovation Organization (BIO), the National Sales Network, Basic Supply Company, Inc., has been recognized as Industry Leader of the Year by the National Hemophilia Foundation, and chaired fundraising for the Boys & Girls Club of Trenton/Mercer County. Mr. Williams earned his B.S. in biology and chemistry from Marshall University.